Pfizer/Allergan deal “inversion” deal catches the eye of US politicians

This week’s announcement of the USD 160bn deal between Pfizer and Allegan has already attracted criticism from US politicians. Given that Republicans and Democrats seem to agree on the issue, could it be something they will try to include in their 2016 campaign pitches?

Is Pfizer looking for another shot of Botox?

News that Pfizer is again interested in merging with Allergan means yet another possible pharma transaction could be on the cards and may result in the creation of the largest pharma company by market capitalisation

Double Advantage Points for Boots in their push into Latin America?

Alliance Boots’ planned acquisition of Farmacias Ahumada could be the start of a European push into Latin America’s pharmaceuticals sector.

Is the takeover of AstraZeneca by Pfizer finally the tonic needed for European M&A?

Pfizer’s latest offer for AstraZeneca may be just what the doctor ordered for European M&A activity and its dealmakers.

Market interest in India’s pharma companies is on the climb again

It’s no surprise to see that pharmaceutical conglomerates around the world have looked in recent times to India for their next big deals